Chemed Co. (NYSE:CHE) insider Kevin J. Mcnamara sold 7,000 shares of the company’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $305.98, for a total value of $2,141,860.00. Following the completion of the sale, the insider now directly owns 141,293 shares in the company, valued at $43,232,832.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NYSE CHE opened at $313.69 on Wednesday. Chemed Co. has a 12 month low of $227.14 and a 12 month high of $335.99. The firm has a market capitalization of $4.94 billion, a PE ratio of 58.52, a P/E/G ratio of 2.69 and a beta of 1.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.11 and a current ratio of 1.14.
Chemed (NYSE:CHE) last released its earnings results on Monday, October 29th. The company reported $3.07 EPS for the quarter, topping analysts’ consensus estimates of $2.80 by $0.27. Chemed had a return on equity of 35.13% and a net margin of 11.73%. The firm had revenue of $444.15 million for the quarter, compared to analysts’ expectations of $445.16 million. During the same period in the prior year, the firm posted $2.15 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, equities analysts anticipate that Chemed Co. will post 11.41 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Monday, November 12th will be paid a $0.30 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.38%. Chemed’s dividend payout ratio is currently 22.39%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP purchased a new stake in shares of Chemed in the second quarter worth $492,000. Marshall Wace LLP purchased a new stake in shares of Chemed during the second quarter valued at $1,433,000. Boston Partners boosted its position in shares of Chemed by 2.7% during the second quarter. Boston Partners now owns 160,271 shares of the company’s stock valued at $51,577,000 after buying an additional 4,186 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its position in shares of Chemed by 20.5% during the second quarter. Public Employees Retirement Association of Colorado now owns 3,376 shares of the company’s stock valued at $1,086,000 after buying an additional 575 shares during the last quarter. Finally, Mutual of America Capital Management LLC boosted its position in shares of Chemed by 68.1% during the second quarter. Mutual of America Capital Management LLC now owns 24,172 shares of the company’s stock valued at $7,779,000 after buying an additional 9,790 shares during the last quarter. 90.39% of the stock is currently owned by hedge funds and other institutional investors.
CHE has been the topic of several recent research reports. Zacks Investment Research raised Chemed from a “hold” rating to a “buy” rating and set a $350.00 price target on the stock in a research note on Tuesday, July 31st. Royal Bank of Canada increased their target price on Chemed to $321.00 and gave the stock a “market perform” rating in a research note on Monday, July 30th. ValuEngine cut Chemed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 2nd. Finally, Bank of America started coverage on Chemed in a research note on Friday, October 12th. They issued a “buy” rating and a $390.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Chemed has an average rating of “Buy” and an average target price of $334.00.
TRADEMARK VIOLATION WARNING: “Kevin J. Mcnamara Sells 7,000 Shares of Chemed Co. (CHE) Stock” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/07/kevin-j-mcnamara-sells-7000-shares-of-chemed-co-che-stock.html.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Article: What is a put option?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.